Dapagliflozin suppresses hepcidin and increases erythropoiesis

Journal of Clinical Endocrinology and Metabolism

Volumn 105, Issue 4, 2020, Pages E1056-E1063

  Ghanim, Husam ^a   Abuaysheh, Sanaa ^a   Hejna, Jeanne ^a   Green, Kelly ^a   Batra, Manav ^a   Makdissi, Antione ^a   Chaudhuri, Ajay ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Dapagliflozin; Erythropoiesis; Hepcidin; Iron

Indexed keywords

CD71 ANTIGEN; DAPAGLIFLOZIN; ERYTHROPOIETIN; FERRITIN; FERROPORTIN; HEMOGLOBIN A1C; HEMOPOIETIC GROWTH FACTOR; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; PROLYL HYDROXYLASE INHIBITOR; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIINFECTIVE AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; EGLN1 PROTEIN, HUMAN; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ERYTHROFERRONE; HEMOGLOBIN; HORMONE; OXYGENASE; PROLYL HYDROXYLASE 2; UNCLASSIFIED DRUG;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOCRINOLOGY; ENZYME INHIBITION; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION LEVEL; RANDOMIZED CONTROLLED TRIAL; CHEMISTRY; DRUG EFFECT; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; FERRITIN BLOOD LEVEL; HUMAN CELL; MEAN CORPUSCULAR VOLUME; MONONUCLEAR CELL; PROTEIN EXPRESSION;

ANTI-INFECTIVE AGENTS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HEPCIDINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85081946127     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgaa057     Document Type: Article

References (18)

1. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8(12):844–847.
2. Heyman SN, Khamaisi M, Rosenberger C, Szalat A, Abassi Z. Increased hematocrit during sodium-glucose cotransporter-2 inhibitor therapy. J Clin Med Res. 2017;9(2):176–177.
3. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087–1095.
4. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862.
5. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPAREG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108–1114.
6. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–1658.
7. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–4433.
8. Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131(8):899–910.
9. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684.
10. Wyatt CM, Drüeke TB. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Kidney Int. 2016;90(5):923–925.
11. Dhindsa S, Ghanim H, Batra M, et al. Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes. Clin Endocrinol (Oxf). 2016;85(5):772–780.
12. Zhang DL, Rouault TA. How does hepcidin hinder ferroportin activity? Blood. 2018;131(8):840–842.
13. Motta G, Zavattaro M, Romeo F, Lanfranco F, Broglio F. Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases. J Clin Endocrinol Metab. 2019;104(3):819–822.
14. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862.
15. Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69–74.
16. Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes. 2019;12:1001–1012.
17. Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–292.
18. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801–1808.